

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Groot et al.

Serial No.: To be assigned

Filed: October 2, 2003

For: GENES INVOLVED IN IMMUNE
RELATED RESPONSES OBSERVED
WITH ASTHMA

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2183-6143US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV325784571US

Date of Deposit with USPS: October 2, 2003

Person making Deposit: Chris Haughton

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

U.S. Patent Documents

| <u>U.S. Patent No.</u> | <u>Publication Date</u> | <u>Patentee</u> |
|-------------------------|-------------------------|-------------------|
| US - US 2002/0034726 A1 | 03-21-2002 | Kanegasaki et al. |

Foreign Patent Documents

| <u>Document No.</u> | <u>Publication Date</u> | <u>Patentee</u> |
|---------------------|-------------------------|----------------------------|
| WO 99/37809 | 07-29-1999 | Axys Pharmaceuticals, Inc. |
| WO 99/62556 | 12-9-1999 | Effector Cell Institute |
| WO 02/14366 A2 | 02-21-2002 | Universiteit Utrecht |
| EP 1 182 255 A1 | 08-16-2000 | Universiteit Utrecht |

Other Documents

KIKLY et al., Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils, Journal of Allergy and Clinical Immunology, June 2000, pp. 1093-1100, Vol. 105, No. 6, Part 1.

LURTON et al., Isolation of a Gene Product Expressed by a Subpopulation of Human Lung Fibroblasts by Differential Display, Am. J. Respir. Cell Mol. Biol., February 1999, pp. 327-31, Vol. 20, No. 2.

WELFORD et al., Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization, Nucleic Acids Research, 1998, pp. 3059-65, Vol. 26, No. 12.

PCT International Search Report, PCT/NL01/00610, dated April 15, 2002.


Attorney Docket No.: 2183-6143US

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, Applicants offer hereby identifies the following listed copending applications naming the same inventor(s):

Attorney Docket No.: 2183-5760US
Serial No.: 10/369,214
Filing Date: February 15, 2003
Title: GENES INVOLVED IN IMMUNE RELATED RESPONSES
OBSERVED WITH ASTHMA

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: October 2, 2003
ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08
Cited Documents

Document in ProLaw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | <i>Complete if Known</i> | |
| | | | | Application Number | To be assigned |
| | | | | Filing Date | October 2, 2003 |
| | | | | First Named Inventor | Groot et al. |
| | | | | Group Art Unit | To be assigned |
| | | | | Examiner Name | To be assigned |
| | | | | Attorney Docket Number | 2183-6143US |
| Sheet | 1 | of | 2 | | |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | | WO 99/37809 | 07-29-1999 | Axys Pharmaceuticals, Inc. | | |
| | | WO 99/62556 | 12-9-1999 | Effector Cell Institute | | |
| | | WO 02/14366 A2 | 02-21-2002 | Universiteit Utrecht | | |
| | | EP 1 182 255 A1 | 08-16-2000 | Universiteit Utrecht | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | To be assigned |
| Filing Date | October 2, 2003 |
| First Named Inventor | Grout et al. |
| Group Art Unit | To be assigned |
| Examiner Name | To be assigned |
| Attorney Docket Number | 2183-6143UIS |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | | KIKLY et al., Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils, Journal of Allergy and Clinical Immunology, June 2000, pp. 1093-1100, Vol. 105, No. 6, Part 1. | |
| | | LURTON et al., Isolation of a Gene Product Expressed by a Subpopulation of Human Lung Fibroblasts by Differential Display, Am. J. Respir. Cell Mol. Biol., February 1999, pp. 327-31, Vol. 20, No. 2. | |
| | | WELFORD et al., Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization, Nucleic Acids Research, 1998, pp. 3059-65, Vol. 26, No. 12. | |
| | | PCT International Search Report, PCT/NL01/00610, dated April 15, 2002. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.